US President's Emergency Plan for AIDS Relief (PEPFAR), the global HIV response has entered a second year of structural transformation. In early 2025, the programme faced the most uncertain period in ...

Lenacapavir is administered twice a year and is designed to provide sustained protection against HIV infection.

By pairing digital tools with tailored HIV services delivered by community health workers and clinicians, a study has reduced new HIV cases by 70% in rural Kenya and Uganda. This successful strategic ...

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to ...

Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...

Dar es Salaam. Tanzania has officially registered Lenacapavir, a long-acting injectable drug for the prevention and control of HIV, marking what officials describe as a significant milestone in the ...

Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to Biktarvy.

Kenya is set to begin the national rollout of the long-acting HIV prevention injection, Lenacapavir, on Thursday, February 26, 2026. However, not everyone at risk will qualify. The Programs Officer, ...

Lawmakers in Georgia, the state with the highest rate of new HIV infections in the country, are moving to allow pharmacists to prescribe and administer HIV prevention drugs.

Zimbabwe, where HIV has led to tens of thousands of deaths over the past two decades, is one of the first countries to roll out lenacapavir, a long-acting drug that authorities hope will slow new ...